Fig. 3

CLL B-cells’ sensitivity to AA is altered by catalase expression. a: catalase protein expression in OSU-CLL and JVM3 cell lines. b: Viability of OSU-CLL cells after AA treatment for 24 h in the presence or absence of catalase (600 U/ml) (**: p < 0.01; n = 6). c: Viability of primary CLL B-cells after treatment with AA for 24 h (***: p < 0.001; n = 40). d: Relative mRNA expression of catalase vs. GAPDH in CLL B-cells from AA-sensitive patients (S-CLL B-cells) or AA-non-sensitive patients (NS-CLL B-cells) and B-cells from healthy donors (HD B-cells). e: Catalase protein expression (normalized against β-actin) in HD B-cells and CLL B-cells (*: p < 0.05, ***: p < 0.001). f: Upper panel: Western blot and quantification of catalase protein levels following treatment of JVM3 cells for 48 h and 72 h with a control siRNA (siCtrl) or siRNA against catalase (siCAT). Relative catalase protein levels were quantified using ImageJ software. Lower panel: At 72 h, siRNA-transfected cells were treated by AA and cell viability was assessed after 24 h using the CellTiter-Glo Luminescent Cell Viability Assay Kit (n = 2 in duplicate). *: p < 0.05, **: p < 0.01. Data are presented as the mean ± SEM